Noticias de SNGX_US

Noticias del mercado

Últimas noticias sobre SNGX_US — 38 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: SNGX_US ✕ 38 resultados
20/04/2026 SNGX_US — Benzinga
Soligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status
14/04/2026 SNGX_US — MSN
Soligenix secures EU orphan drug designation for Behçet’s disease therapy
11/04/2026 SNGX_US — openPR.com
Mycosis Fungoides Treatment Market Surges to US$ 3.42 Billion
10/04/2026 SNGX_US — MarketScreener
BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
10/04/2026 SNGX_US — ChartMill
BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
10/04/2026 SNGX_US — ACCESS Newswire ES ← EN
Las entrevistas de BIO-key International, 20/20 Biolabs, Society Pass y Soligenix se transmitirán en el programa RedChip Small Stocks, Big Money(TM) en Bloomberg TV
10/04/2026 SNGX_US — Corsicana Daily Sun
BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
08/04/2026 SNGX_US — TradingView
SNGX: Late-stage pipeline addresses rare diseases and public health, backed by strong clinical data
06/04/2026 SNGX_US — Yahoo Finance
SNGX: Interim Analysis for Phase 3 CTCL Study in 2Q26
03/04/2026 SNGX_US — news.google.com
SNGX Stock Analysis: Soligenix Inc biotech stock trades at $1.14 after 0.87% minor daily dip
03/04/2026 SNGX_US — Stock Titan
[EFFECT] SOLIGENIX, INC. SEC Filing
02/04/2026 SNGX_US — Investing.com UK ES ← EN
Un estudio de HyBryte muestra una respuesta más rápida frente a Valchlor en un ensayo sobre linfoma Por Investing.com
02/04/2026 SNGX_US — Barchart.com
Soligenix (NASDAQ: SNGX) Publishes Positive HyBryte Study Results In Oncology and Therapy
02/04/2026 SNGX_US — Investing.com
HyBryte study shows faster response vs Valchlor in lymphoma trial
02/04/2026 SNGX_US — Seeking Alpha
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy (2026-04-02)
02/04/2026 SNGX_US — Nasdaq ES ← EN
Resultados clínicos positivos del estudio comparativo de HyBryte™ que evalúa HyBryte™ frente a Valchlor® en el tratamiento del linfoma cutáneo de células T publicado en Oncology and Therapy
02/04/2026 SNGX_US — PR Newswire
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
31/03/2026 SNGX_US — Bitget ES ← EN
Soligenix anuncia logros recientes y resultados financieros de fin de año 2025
31/03/2026 SNGX_US — PR Newswire
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
31/03/2026 SNGX_US — Investing.com
Soligenix reports 2025 results, eyes Q2 trial data

Página 1 de 2

keyboard_arrow_up